Augmedix Statistics
Total Valuation
Augmedix has a market cap or net worth of $48.08 million. The enterprise value is $36.35 million.
| Market Cap | 48.08M |
| Enterprise Value | 36.35M |
Important Dates
The next estimated earnings date is Monday, August 5, 2024, after market close.
| Earnings Date | Aug 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Augmedix has 48.97 million shares outstanding. The number of shares has increased by 41.52% in one year.
| Shares Outstanding | 48.97M |
| Shares Change (YoY) | +41.52% |
| Shares Change (QoQ) | +8.11% |
| Owned by Insiders (%) | 6.30% |
| Owned by Institutions (%) | 88.68% |
| Float | 28.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.99 |
| Forward PS | 0.75 |
| PB Ratio | 2.70 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.04, with a Debt / Equity ratio of 1.44.
| Current Ratio | 2.04 |
| Quick Ratio | 1.93 |
| Debt / Equity | 1.44 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.29 |
Financial Efficiency
Return on equity (ROE) is -178.30% and return on invested capital (ROIC) is -46.21%.
| Return on Equity (ROE) | -178.30% |
| Return on Assets (ROA) | -38.70% |
| Return on Capital (ROIC) | -46.21% |
| Revenue Per Employee | $34,055 |
| Profits Per Employee | -$14,287 |
| Employee Count | 1,430 |
| Asset Turnover | 0.92 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Augmedix has paid $32,000 in taxes.
| Income Tax | 32,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.86% in the last 52 weeks. The beta is -0.22, so Augmedix's price volatility has been lower than the market average.
| Beta (5Y) | -0.22 |
| 52-Week Price Change | -80.86% |
| 50-Day Moving Average | 1.51 |
| 200-Day Moving Average | 3.96 |
| Relative Strength Index (RSI) | 43.40 |
| Average Volume (20 Days) | 437,276 |
Short Selling Information
The latest short interest is 1.59 million, so 3.24% of the outstanding shares have been sold short.
| Short Interest | 1.59M |
| Short Previous Month | 1.54M |
| Short % of Shares Out | 3.24% |
| Short % of Float | 5.61% |
| Short Ratio (days to cover) | 1.20 |
Income Statement
In the last 12 months, Augmedix had revenue of $48.70 million and -$20.43 million in losses. Loss per share was -$0.43.
| Revenue | 48.70M |
| Gross Profit | 23.48M |
| Operating Income | -20.09M |
| Pretax Income | -20.40M |
| Net Income | -20.43M |
| EBITDA | -15.53M |
| EBIT | -17.94M |
| Loss Per Share | -$0.43 |
Balance Sheet
The company has $37.43 million in cash and $25.69 million in debt, giving a net cash position of $11.74 million or $0.24 per share.
| Cash & Cash Equivalents | 37.43M |
| Total Debt | 25.69M |
| Net Cash | 11.74M |
| Net Cash Per Share | $0.24 |
| Equity (Book Value) | 17.78M |
| Book Value Per Share | 0.36 |
| Working Capital | 25.45M |
Cash Flow
In the last 12 months, operating cash flow was -$17.46 million and capital expenditures -$3.47 million, giving a free cash flow of -$20.93 million.
| Operating Cash Flow | -17.46M |
| Capital Expenditures | -3.47M |
| Free Cash Flow | -20.93M |
| FCF Per Share | -$0.39 |
Margins
Gross margin is 48.22%, with operating and profit margins of -41.25% and -41.95%.
| Gross Margin | 48.22% |
| Operating Margin | -41.25% |
| Pretax Margin | -41.89% |
| Profit Margin | -41.95% |
| EBITDA Margin | -31.89% |
| EBIT Margin | -36.84% |
| FCF Margin | -42.98% |
Dividends & Yields
Augmedix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -41.52% |
| Shareholder Yield | -41.52% |
| Earnings Yield | -42.49% |
| FCF Yield | -43.53% |
Analyst Forecast
The average price target for Augmedix is $4.67, which is 375.61% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.67 |
| Price Target Difference | 375.61% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Augmedix has an Altman Z-Score of -2.53 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.53 |
| Piotroski F-Score | 4 |